AngioDynamics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US03475V1017
USD
13.37
0.08 (0.6%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About AngioDynamics, Inc. stock-summary
stock-summary
AngioDynamics, Inc.
Pharmaceuticals & Biotechnology
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company's devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Vascular Interventions & Therapies, Vascular Access and Oncology. The Company's Vascular Interventions & Therapies products include Venous, Thrombus Management, as well as other core products. The Company's BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines. Through its subsidiary, Eximo Medical, Ltd., the Company operates 355 nanometers (nm) wavelength laser-technology platform.
Company Coordinates stock-summary
Company Details
14 Plaza Dr , LATHAM NY : 12110-2166
stock-summary
Tel: 1 518 79812151 518 7951408
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 53 Schemes (46.45%)

Foreign Institutions

Held by 82 Foreign Institutions (14.61%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Howard Donnelly
Independent Chairman of the Board
Mr. James Clemmer
President, Chief Executive Officer, Director
Ms. Eileen Auen
Independent Director
Mr. Wesley Johnson
Independent Director
Ms. Karen Licitra
Independent Director
Mr. Dennis Meteny
Independent Director
Ms. Jan Reed
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
80 Million
(Quarterly Results - May 2025)
Net Profit:
-6 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 447 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.30

stock-summary
Return on Equity

-9.89%

stock-summary
Price to Book

2.44